IDSA, the Society for Healthcare Epidemiology of America, and the Pediatric Infectious Diseases Society were recently awarded a contract from the Centers for Disease Control and Prevention to continue the Leaders in Epidemiology, Antimicrobial Stewardship, and Public Health (LEAP) Fellowship through the 2020-2021 academic year.

The LEAP Fellowship is a 1-year funded training program, aimed at developing late-stage ID trainees and early-stage ID physicians into health care leaders capable of working as clinical partners to local and national public health agencies.

Applicants are being sought for the LEAP program for the upcoming 2020-2021 academic year. Application criteria are still being finalized; however, preliminary criteria are as follows:

  • Applicants must be physicians between their first year of ID fellowship and up to two years post fellowship.
  • Applicants must be associated with an Infectious Diseases training program, and with a health care facility with robust antibiotic stewardship, infection control, and/or hospital epidemiology programs.
  • Applicants must have or be in the process of establishing a relationship with state or local health departments.

Final application instructions and criteria will be sent out in late 2019. The most up-to-date information can be obtained by visiting IDSA’s LEAP Fellowship webpage or by contacting LEAP Fellowship Program Manager Michele Wagner, at: This email address is being protected from spambots. You need JavaScript enabled to view it..

Dr. Kris Bryant

It is the season to be grateful and I’m making a list.

First, I am thankful and incredibly honored to serve as the next President of the Pediatric Infectious Diseases Society.  Our society has been fortunate to have a history of strong and innovative leadership.  Paul Spearman is both a mentor to me and a tough act to follow!  I’m looking forward to growing initiatives that he championed around member engagement and advocacy.  I couldn’t ask for better partners than President-elect, Buddy Creech, and Secretary-Treasurer, Susan Coffin.

I am thankful for our hardworking and resourceful staff, Executive Director, Christy Phillips, and Marketing and Communications Manager, Winter Harris.  It is a little mind-boggling to consider that PIDS and the PIDS Foundation are run with a permanent staff of two.  Fortunately, we have dozens of dedicated volunteers who do much of the work that supports our strategic aims.  In the coming year, I hope to bring you a formal strategic plan that will help us prioritize our work and potentially grow our resources.

Finally, I am thankful to be able to work in this profession.  I always tell trainees that I have the best job in the world.  One of the things I appreciate about this field, is that my “best” job doesn’t necessarily look like your “best” job.  As pediatric infectious diseases specialists, some of us work in large academic medical centers.  Others work in smaller community hospitals.  Some of us are employed by industry or public health partners.  Some of us move our field forward by leading NIH-funded research labs and others advance the field through clinical trials (or contribute data to multi-center clinical trials).  We are educators.  We are policymakers.  We are entrepreneurs.  In future newsletters, I plan to highlight the breadth of opportunity and talent in our profession with profiles of members who work in a variety of settings.  Yes, I hope this sort of storytelling will be valuable as we think about how best to recruit trainees to our fellowship programs.  I also hope to “introduce” you to fellow Peds ID specialists that maybe you haven’t had a chance to meet in person, or perhaps I'll help you learn something about a longtime colleague that you didn’t know.  I also want to make it clear—if it wasn’t already—that all are welcome in PIDS.

As 2019 draws to a close, if you have ideas for me, questions or concerns to share, please reach out.  We have some exciting projects on the horizon… but more about those next time.



PIDS Journal Club, September 2019

Oral linezolid for routine treatment of uncomplicated Staphylococcus aureus bacteremia? Not ready yet.

Reviewing: Willekens R, et al, “Early oral switch to linezolid for low-risk patients with Staphylococcus aureus bloodstream infections: a propensity-matched cohort study”, Clin Infect Dis, 20181


Management of apparently uncomplicated Staphylococcus aureus bacteremia (SAB) is challenging because relapse is common, probably related to unrecognized deep-seated infection .2 As oral antibiotic therapy is increasingly used for bloodstream infections, oral treatment for SAB is under consideration.3 In the pediatric world, infectious diseases physicians report using oral therapy for bacteremic osteomyelitis, but not proven SAB without a bony focus.4 This study, by Willekens et al, evaluated the effectiveness of oral linezolid, a highly bioavailable anti-staphylococcal antibiotic, to complete treatment of SAB in adults after initial parenteral therapy.1

Methods and Results

This was a subgroup analysis of a prospective observational cohort study comprising adults with SAB; it included participants judged to be at low risk of complications who received either entirely parenteral antibiotics or were switched to oral linezolid after 3-9 days of parenteral therapy at treating clinician discretion. The primary outcome was relapse of S. aureus infection within 90 days, and secondary outcomes included length of hospital stay (LOS), and 14- or 30-day mortality. A propensity score-matched sub cohort matched linezolid-treated participants with the two “most similar” parenteral-treated participants.

A total of 152 participants were identified (45 linezolid and 107 parenteral therapy); 135 were included in the propensity-matched sub cohort. Participants were treated for a median of 15 days in each group. Risk factors for treatment failure (e.g. chronic renal failure, risk factors for endovascular infection, unknown BSI source, sepsis and ICU admission) were much more common in the parenteral therapy group, even after propensity score matching. Although not statistically significant, patients who received oral linezolid were slightly less likely to have relapse of infection (RR 0.5; P=0.9) or to die by 14 days (RR ∞; P=0.2) or 30 days (RR 0.17; P=0.08). They did have significantly shorter median LOS (8 vs. 19 days; P<0.01). The authors concluded that treatment of SAB in selected low-risk patients with an oral switch to linezolid after initial parenteral therapy yielded similar clinical outcomes as parenteral therapy.


The main problem with interpreting this study is the possibility of indication bias.5 Clinicians appear to have been more inclined to give conservative (parenteral) therapy to participants at higher risk of treatment failure; there are differences in baseline characteristics and 14-day mortality (before any likely effect of the treatment). The authors did attempt to address this with propensity score matching but, because they had only a small group of potential matches and did not require close matching, the groups remained very different. Propensity score matching relies on selecting a comparator group that is similar to the intervention group.6 Other issues include unknown applicability to pediatric patients and to other special populations such as patients with neutropenia or other immunocompromise.


The study does not prove that oral linezolid is as safe and effective as parenteral therapy for treatment of SAB, since the patients receiving oral linezolid might have had a better chance of success.  It may provide some justification for occasional use following a short course of IV therapy, and sets the stage for a prospective randomized non-inferiority study (e.g. NCT01792804)7, but I will wait for those results before routinely using oral linezolid as completion therapy for uncomplicated SAB.

Share your thoughts about this review on our PIDS Connect community forum!



St. Jude Children’s Research Hospital, Memphis, TN, USA 

Peer Reviewers

Sandra L Arnold MD (Le Bonheur Children’s Medical Center, Memphis, TN, USA)

Suchitra Rao MBBS, MSCS (Children’s Hospital Colorado, Aurora, CO, USA)


  1. Willekens R, Puig-Asensio M, Ruiz-Camps I, Larrosa MN, Gonzalez-Lopez JJ, Rodriguez-Pardo D, et al. Early oral switch to linezolid for low-risk patients with Staphylococcus aureus bloodstream infections: a propensity-matched cohort study. Clin Infect Dis. 2018.
  2. Berrevoets MAH, Kouijzer IJE, Aarntzen E, Janssen MJR, De Geus-Oei LF, Wertheim HFL, et al. (18)F-FDG PET/CT Optimizes Treatment in Staphylococcus Aureus Bacteremia and Is Associated with Reduced Mortality. J Nucl Med. 2017;58(9):1504-1510.
  3. Hospenthal DR, Waters CD, Beekmann SE, Polgreen PM. Practice patterns of infectious diseases physicians in transitioning from intravenous to oral therapy in patients with bacteremia. Open Forum Infect Dis. 2019.
  4. Wood JB, Fricker GP, Beekmann SE, Polgreen P, Buddy Creech C. Practice Patterns of Providers for the Management of Staphylococcus aureus Bacteremia in Children: Results of an Emerging Infections Network Survey. Journal of the Pediatric Infectious Diseases Society. 2018;7(3):e152-e155.
  5. Walker AM. Confounding by indication. Epidemiology. 1996;7(4):335-336.
  6. Joffe MM, Rosenbaum PR. Invited commentary: propensity scores. Am J Epidemiol. 1999;150(4):327-333.
  7. Staphylococcus Aureus Bacteremia Antibiotic Treatment Options (SABATO). Published 2013. Accessed September 16, 2019.



For Immediate Release: September 5, 2019

Contact: Christy Phillips, (703) 299- 9865, This email address is being protected from spambots. You need JavaScript enabled to view it.


Pediatric Infectious Diseases Society Honors Six Distinguished Physicians, Scientists

The world's largest organization of professionals dedicated to the treatment, control and eradication of infectious diseases affecting children, the Pediatric Infectious Diseases Society, has honored six distinguished physicians and scientists from the United States and around the world who were elected this year to be fellows of PIDS. 

The designation “fellow” in PIDS honors those who have achieved professional excellence and provided significant service to the profession. “PIDS fellows are national and international leaders and experts in the field of pediatric infectious diseases. Their expertise touches the lives of children not only on those larger stages, but also at the local level in their hospitals, clinics, research labs, institutions, and communities,” said PIDS President Paul W. Spearman, MD, FPIDS. “Fellowship in PIDS is our way of recognizing these accomplished physicians, researchers, and scientists for their important contributions to our field.” 

Applicants for PIDS fellowship must be nominated by their peers and meet specified criteria, including continuing identification with the field of pediatric infectious diseases, national or local recognition, and publication of their work in strong biomedical journals. Nominees are reviewed and elected by the PIDS Board of Directors. Fellows of PIDS work in many different settings, including clinical practice, teaching, research, public health, and health care administration.

This year, the following individuals were honored as fellows of PIDS:

Nazha Abughali, MD, FPIDS

Ann Chahroudi, MD, PhD, FPIDS

Stephanie Fritz, MD, MS, FPIDS

David P. Greenberg, MD, FPIDS

Dean L. Winslow, MD, FPIDS

Joshua Wolf, MBBS, FPIDS




About PIDS

PIDS membership encompasses leaders across the global scientific and public health spectrum, including clinical care, advocacy, academics, government, and the pharmaceutical industry. From fellowship training to continuing medical education, research, regulatory issues and guideline development, PIDS members are the core professionals advocating for the improved health of children with infectious diseases both nationally and around the world, participating in critical public health and medical professional  advisory committees that determine the treatment and prevention of infectious diseases, immunization practices in children, and the education of pediatricians. For more information, visit


The PIDS Foundation Board of Trustees invites you to Party on the Potomac!  An evening of fun, fellowship and discussion of vaccine challenges in the 21st century.  Our guest speaker, Dr. Peter Hotez, will describe recent changes to the pediatric and adult vaccine schedules, focusing primarily on newer vaccine technologies and vaccine adjuvants and share common misconceptions regarding vaccine safety.  In addition to the mini-lecture, The PIDS Distinguished Physician and Young Investigator Awards will be presented.

Here are 5 reasons why should you attend:

  1. Meet your old Pediatric ID friends
  2. Make new Pediatric ID friends
  3. Share fond memories with PIDS members and other colleagues
  4. Network…for research ideas, for job opportunities, for FUN
  5. "Grab a prop and strike a pose” at the ID-themed photo booth


One more thing: we have some PIDS gear!  We will have PIDS-branded hats, water bottles, ties, and scarves available for a small donation to the PIDS Foundation. Please visit the PIDS booth or pick up your PIDS swag at the dinner celebration.

We hope to see you there!

Janet Gilsdorf, MD
PIDS Foundation Chair
Paul Spearman, MD
PIDS President
PIDS would like to thank our sponsors, Horizon Therapeutics, Karius, and Sanofi Pastuer, for their generous support.

For Health Care Professionals: Preparing Your Practice/Fight Flu Toolkit

As healthcare professionals prepare to have conversations with patients around flu vaccination, CDC has pulled together a suite of digital and print-off materials to help in effectively conveying the threat of flu and why flu vaccination is so important. 

These resources include:

For the General Public/Patients: CDC Digital Media Toolkit

We have updated this webpage and related social media images and messages to reflect the upcoming flu season. 


CDC is currently collecting a variety of Flu Fighter profiles through partners, describing how members of the American public have been affected by flu and why they fight the often devastating disease. We are aiming to post these profiles after the annual flu vaccination season kickoff press conference hosted by NFID on 9/26.

This hashtag campaign is focused on reinforcing the negative impact of flu and positive benefits of flu vaccine. In that vein, we are inviting all of our partners to use the hashtag #WhyIFightFlu and share an answer to the question "why do you fight flu?" as we move forward with flu season.



  • August 28, 2019: To conclude National Immunization Awareness Month (NIAM), CDC is hosting a webinar on 8/28 focused on addressing vaccine hesitancy in the practice. This will not be flu-specific, but will have some overarching strategies on addressing vaccine misinformation. More information and registration here.
  • September 26, 2019: Watch and promote the livestream of the annual flu vaccination season kickoff press conference hosted by the National Foundation for Infectious Diseases (NFID). Link will be shared closer to the kickoff.
  • December 1-7, 2019: Join CDC in promoting flu vaccination before and during National Influenza Vaccination Week (NIVW). NIVW-specific updates, events, and resources will be posted on CDC's NIVW website.
  • TBD: Webinar focused on talking through the many different flu vaccines for the 2019-20 flu season and making a strong flu vaccine recommendation – tentatively set for early October; more details coming soon
  • Throughout flu season: We will be sharing stories of why members of the American public fight flu with the hashtag #WhyIFightFlu

The CDC released results from the National Immunization Survey-Teen (NIS-Teen) in the Morbidity and Mortality Weekly Report, which provides the latest estimates of vaccination rates among adolescents in the United States.

The key findings from the report include:

  • HPV vaccination rates increased slightly, but there was no increase in rates among girls, highlighting the need for continued efforts to ensure all boys and girls are vaccinated on time.
  • Vaccination rates are lower in rural areas, and differ by insurance status.
  • This report reinforces the important role that healthcare professionals can play in increasing vaccination rates and addressing disparities.

Based on the findings, everyone has a role to play in improving vaccination rates. CDC is emphasizing the following calls to action:

Call to Action: Public health programs should work with doctors and their practices to develop better tools to meet the needs of parents to encourage vaccine acceptance. 

  • Parents
    • Ask your child’s doctor about the HPV vaccine when they are 11 or 12 years old.
  • Immunization Programs and Partners
    • Share resources with healthcare professionals to support them in making effective vaccine recommendations and addressing parents’ questions.
    • Partner with organizations focused on rural health to disseminate resources to healthcare professionals in rural areas.
    • Remind parents about the vaccines that are recommended for their child before the start of the school year.

This week’s MMWR also included a report on the latest estimates of HPV cancers in the United States, which found that HPV vaccination could prevent 92% of cancers estimated to be caused by HPV.

To support healthcare professionals in making effective recommendations, addressing parents’ questions and concerns, and reinforce the message that HPV vaccination is cancer prevention, CDC has developed a number of educational resources, which can be found here. Below are a few specific resources we’d like to highlight to assist you in your efforts to reach healthcare professionals and parents.

Resources for Healthcare Professionals

Resources for Parents

Last week, CDC published updated recommendations for HPV vaccination of adults in the MMWR: CDC has updated its web content to reflect the latest recommendations among adults, including developing a new HPV Vaccine Schedules and Dosing page for healthcare professionals to outline HPV vaccine recommendations and guidance for how to talk with parents and patients about vaccine recommendations.

Finally, we encourage you to attend, and inform your members about, next week’s webinar on Strategies for Addressing Vaccine Misinformation in the Practice Setting.

August 21, 2019


Customs and Border Patrol’s Flu Vaccine Policy Breaches Basic Public Health Tenet


Statement from IDSA President Cynthia Sears, MD, FIDSA, HIVMA Chair W. David Hardy, MD, SHEA President Hilary Babcock, MD, MPH, FIDSA, FSHEA, PIDS President Paul Spearman, MD, FPIDS, and ASTMH President Chandy C. John, MD, MS:

The U.S. Customs and Border Patrol’s decision to withhold vaccinations against seasonal influenza from migrants in border detention facilities is a violation of the most basic principles of public health and human rights. It runs directly counter to the imperative that no individual should be harmed as a result of being detained, and that the community standard of medical care be available to persons in the custody of the U.S. government.

An essential tool in protecting both individual and public health, vaccinations against potentially life-threatening and preventable illnesses are an indispensable component of routine healthcare. Since 2010, the U.S. Centers for Disease Control and Prevention has recommended annual influenza vaccination for ALL persons 6 months of age or older in the absence of medical reasons not to be vaccinated, a recommendation that, as organizations of more 16,000 infectious diseases specialists, we stand firmly behind. According to the CDC, seasonal influenza was associated with over 57,000 deaths – 129 in children—during the recent 2018-2019 season. In conditions of overcrowding poor sanitation and emotional stress involving vulnerable populations such as pregnant women and young children, choosing not to follow the CDC recommendations is particularly egregious.

The Infectious Diseases Society of America, the HIV Medicine Association, the Pediatric Infectious Diseases Society, the Society for Healthcare Epidemiology of America, and the American Society of Tropical Medicine and Hygiene call for the immediate articulation and implementation of a plan to administer vaccinations against seasonal influenza and to ensure the delivery of all other routine medical immunizations in facilities under the oversight of U.S. Customs and Border Patrol. We remain deeply concerned about the treatment of immigrants at our borders and in federal detention, and we call for a comprehensive investigation of the agency’s protocol for providing health care at its facilities.



IDSA: Jennifer Morales 
This email address is being protected from spambots. You need JavaScript enabled to view it. 
(703) 299-0412

PCI: Lauren Martin
(312) 558-1770 
This email address is being protected from spambots. You need JavaScript enabled to view it.

View Press Release PDF copy

Statement from IDSA President Cynthia Sears, MD, FIDSA, HIVMA Chair W. David Hardy, MD, SHEA President Hilary Babcock, MD, MPH, FIDSA, FSHEA, and PIDS President Paul Spearman, MD, FPIDS:


Press Release


Embargoed 1 PM ET                                                                                         Contact: CDC Media Relations

July 9, 2019                                                    July 9, 2019                                                                                                                                (404) 639-3286


CDC Urges Doctors to Rapidly Recognize and Report AFM Cases

Intense effort underway to understand and prevent this serious neurologic syndrome

As the late summer/early fall “season” for acute flaccid myelitis (AFM) nears, CDC is calling on medical professionals to quickly recognize AFM symptoms and report all suspected cases to their health department. Early recognition and reporting are critical for providing patients with appropriate care and rehabilitation, and better understanding AFM, according to a new Vital Signs report.

The majority of AFM patients are previously healthy children who had respiratory symptoms or fever consistent with a viral infection less than a week before they experienced limb weakness. Since AFM can progress quickly from limb weakness to respiratory failure requiring urgent medical intervention, rapidly identifying symptoms and hospitalizing patients are important.

Dr. Robert Redfield, CDC Director


“Timing is key for responding to AFM and outbreaks. The quicker doctors recognize symptoms, collect specimens, and report suspected cases to health departments, the more insight we gain into this serious illness,” said CDC Director Robert Redfield, M.D. “AFM is a national public health priority. CDC is working with the AFM Task Force to strengthen the knowledge base about how viruses cause AFM, and best practices around patient treatment and rehabilitation.”


Late summer and early fall is AFM “season”

CDC began tracking AFM in 2014, when the first outbreak of 120 cases occurred. Another outbreak occurred in 2016 with 149 cases, and again with 233 patients in 41 states in 2018– the largest outbreak so far. AFM cases have so far followed a seasonal and biennial pattern, spiking between August and October every other year.

In an analysis of cases confirmed in 2018, CDC detected enteroviruses and rhinoviruses in nearly half of respiratory and stool specimens. Of the 74 cases with a cerebral spinal fluid specimen, only two were positive for enteroviruses (EV-A71 and EV-D68). CDC and other scientists continue to investigate how enteroviruses, including EV-D68, might initiate AFM. All specimens tested negative for poliovirus, a related enterovirus that can cause AFM. 

Dr. Tom Clark, deputy director, Division of Viral Diseases


“Our thorough investigation of AFM will help lead to more answers about this severe disease,” said Tom Clark, M.D., M.P.H, deputy director, Division of Viral Diseases. “We are monitoring AFM trends and the clinical presentation, conducting research to identify possible risk factors, using advanced lab testing and research to understand how viral infections may lead to AFM, and tracking long-term outcomes of AFM patients.”


CDC, with experts from the National Institutes of Health, academia, health departments, and parent advocacy groups, is committed to increasing awareness of AFM, and moving national priorities forward to advance our understanding of AFM and its prevention, treatment, and outcomes.

To read more about the Nationwide Outbreak of Acute Flaccid Myelitis—United States, 2018 and the entire Vital Signs report, visit

About Vital Signs

Vital Signs is a report that appears as part of the CDC’s Morbidity and Mortality Weekly Report. Vital Signs provides the latest data and information on key health indicators.







//IDSA / HIVMA /PIDS logos//

June 24, 2019

Physicians, Health Providers and Researchers Call on Presidential Candidates to Back Funding, Preparedness and Evidence-based Responses to Infectious Diseases, HIV

Contact IDSA: Jennifer Morales This email address is being protected from spambots. You need JavaScript enabled to view it. (703) 299-0412 PCI Public Relations (312) 558-1770  This email address is being protected from spambots. You need JavaScript enabled to view it.

In a bipartisan-aimed petition, more than 500 members of the Infectious Diseases Society of America, its HIV Medicine Association and the Pediatric Infectious Diseases Society are calling on all presidential candidates to commit themselves to public health policies, programs, and investments necessary to protect the lives and health of Americans and reduce the impact of infectious diseases globally, including from the threats of growing and emerging infectious diseases, vaccine preventable diseases, infections increasingly resistant to existing treatments, as well as from the impacts of climate change.

Urging strong stances, support and funding for public health measures against leading domestic and global health challenges, the signers urge White House aspirants to articulate their priorities for tackling infectious diseases opportunities and threats, including with interventions to:

  • Increase vaccine access and uptake;
  • Strengthen responses to the opioid crisis and associated infectious disease impacts;
  • Build antibiotic stewardship, research and development;
  • Sustain U.S. leadership of global HIV and TB responses, while enhancing global health security efforts;
  • Expand interventions to reverse increased rates of sexually transmitted diseases;
  • Use existing tools to end the HIV epidemic and eliminate hepatitis C virus in America;
  • Confront climate change;
  • And build the infectious diseases and HIV trained health workforce necessary to meet these challenges.

The full petition, with further information on infectious diseases priorities and actions, is here.


11th Annual International Pediatric Antimicrobial Stewardship Conference - June 4-5, 2020


To Register, visit:

This course is designed for pediatricians, general practitioners, family practitioners, infectious disease and critical care specialists to improve antimicrobial prescribing for all children. This will be accomplished by increasing the knowledge and competence of individuals beginning an antimicrobial stewardship program. Additionally, the course is designed to improve the performance of current antimicrobial stewardship programs.  At the conclusion of this activity attendees should be able to:

  • List the antimicrobial stewardship strategies utilized to improve antimicrobial prescribing in all healthcare settings.
  • Discuss the important communication techniques to improve antimicrobial prescribing in all healthcare settings.
  • Describe the current rates of antimicrobial resistance and adverse drug reactions in children.


This activity has been planned and implemented by the Pediatric Infectious Diseases Society (PIDS), Society of Infectious Diseases Pharmacists (SIDP), and Washington University School of Medicine in St. Louis. Washington University School of Medicine in St. Louis is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

American Medical Association (AMA)
Washington University School of Medicine in St. Louis designates this live activity for a maximum of 12.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Nurses Credentialing Center (ANCC)
Washington University School of Medicine in St. Louis designates this live activity for a maximum of 12.00 contact hours.

Accreditation Council for Pharmacy Education (ACPE)
This activity is approved for 12.25 contact hours (1.225 CEUs) in states that recognize ACPE. Attending the full program will earn 12.25 contact hours (1.225 CEUs), UAN –#. To be awarded credit, attendees must have participated in all sessions, complete the activity evaluation, and provide your NABP ePID number and date of birth.

Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 12.5 Interprofessional Continuing Education (IPCE) credits for learning and change.


Record Number of Abstracts Submitted to 2019 Antimicrobial Stewardship Conference - St. Louis, MO

During this year's Antimicrobial Sterwardship Conference, We had a record number of participants (220) and abstracts (77) this year. Leading experts from around the country discussed important antimicrobial stewardship topics including Gram-negative resistance (Latania Logan MD), stewardship for the pediatric intensive care unit (Kathleen Chiotos MD) and communication insights for stewards (Julia Szymczak, PhD). The three Pediatric ID ASP Fellow award winners (Rebecca Same, MD, Sophie Katz, MD and Maria Equiguren Jimenez, MD) presented their outstanding research.   Two ASP conference attendees had the following to say about the 2019 conference:

"This was my first time attending this conference.  I absolutely loved it. It was for two days so not too long. Lectures were all pediatric relevant and in line with ASP priorities.  Networking with colleagues in other places is invaluable. Will surely go back next year!"  ~ Dr. Upadhyayula
"The PIDS ASP conference was a fantastic opportunity to talk to other stewards about their programs and research and discuss some of the obstacles that we face at my home institution. I came away from the conference with multiple ideas for our program from small tweaks to larger policy goals." ~ Dr. TeKippe



Please be aware that is the only official site for registering for IDWeek 2019. Experient is the official housing provider for IDWeek 2019 and their site can only be accessed through International groups can also use for housing and travel assistance.

Fraudulent websites have been reported, so it is critical that you use only the official IDWeek websites mentioned above to register for the meeting and for booking a hotel reservation through IDWeek. We do not ask for member identification numbers during registration, and no one will email you to ask for your membership password. Please do not provide this information if requested, and be aware that you are using an illegitimate website.

IDWeek cannot guarantee your registration or housing if you purchase using an illegitimate website.

IDWeek staff make every effort to shut down illegitimate websites as soon as we are made aware of them; however, new attempts to create fraudulent sites occur regularly. If you are concerned about your registration, please contact IDWeek staff at This email address is being protected from spambots. You need JavaScript enabled to view it..

Dear Colleagues:


We are in the midst of an upsurge in measles in the US, thanks largely to the dedicated misinformation efforts of the anti-vaccine movement. I wonder if we could learn from the history of polio vaccination as we try to fight the rise in vaccine hesitancy in this country. A little local history from here in Cincinnati might help. On April 24, 1960, Albert Sabin participated in the initial rollout of the oral polio vaccine he had developed at Cincinnati Children’s Hospital on the first “Sabin Sunday.” He was surprised at the huge lines of parents bringing their children in for his vaccine, and by the end of the day more than 20,000 local children had received the vaccine. Vaccine uptake eventually became so universal that polio was eradicated from the Western hemisphere and from most of the world. What is different now? I think one major factor is that severe disease from measles does not seem real to most Americans, and very few have seen it affect themselves or their neighbors. In the case of polio, there was great fear of the crippling effects that could result from the infection, and this fear plus perhaps a healthy respect for science led to enthusiastic vaccine uptake. It seems that right now our communities could use a healthy dose of fear of the infectious diseases that our vaccines can now prevent, along with real education about vaccine safety to counteract misinformation from the anti-vaxxers. One of our key missions at PIDS is to promote vaccine uptake in order to save the lives of children, and as a society we stand firmly against non-medical vaccine exemptions. Let’s help think of ways to also educate our communities about the seriousness of vaccine-preventable diseases, as we seek always to build trust in the safety and efficacy of vaccines.



Dr. Paul Spearman

PIDS Board President

Dear Provider,

Due to the current increase in measles cases in the United States (, the Centers for Disease Control and Prevention has developed the following summary for vaccination of adults against measles with measles, mumps, rubella (MMR) vaccine. Recommendations for vaccination and assessing immunity in adults have not changed since publication of the Advisory Committee on Immunization Practices (ACIP) recommendations for the Prevention of Measles, Rubella, Congenital Rubella syndrome, and Mumps in June 2013. (


Providers do not need to actively screen adult patients for measles immunity.  This is because of high population immunity and low risk of disease among adults in non-outbreak areas in the U.S.

Providers should make sure patients have measles protection before international travel.  U.S. residents traveling internationally are at high risk for acquiring measles abroad.  They can also transmit measles to susceptible persons, such as infants, when they return home.

If a patient is traveling internationally and measles immunity is unknown, providers should vaccinate, unless there are contraindications.  Serologic testing for measles immunity is not recommended.

During outbreaks, providers should consult with local health departments for the most up-to-date recommendations for their community.  This may include additional doses of MMR for your patients.  

To download and print this letter in its entirety, click here.